Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.
Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback